CCF Corner

The Cholangiocarcinoma Foundation (CCF) is pleased to announce the 11th Annual Cholangiocarcinoma Foundation Conference in Salt Lake City, UT, April 17-19, 2024.

The Cholangiocarcinoma Foundation (CCF) is celebrating the 1000th mentor–mentee match and 6 years of their mentoring program, CholangioConnect. CCF has developed unique resources to help patients and caregivers navigate their healthcare journeys.

Cancer investigators and clinicians from around the world connected with patients, caregivers, and industry officials at the foundation’s conference in Salt Lake City, UT.

CCF discusses the approval of durvalumab for cholangiocarcinoma, a milestone that, it is hoped, will open doors for other innovative immunotherapy combinations.

A group of 29 expert scientists and clinicians from the world’s leading academic institutions developed potentially transformative project proposals while gathered in Las Vegas for a 2-day meeting called Cure Cholangiocarcinoma Think Tank (C²T²).

The Cholangiocarcinoma Foundation hosts a patient registry, the International Cholangiocarcinoma Patient Registry (ICPR), that is a global database comprising patient medical histories and treatments for cholangiocarcinoma (CCA).

There is a desperate need for patients with CCA to gain access to clinical trials to help improve survival.

At the 2022 Cholangiocarcinoma Foundation (CCF) Annual Conference on February 22-25, Melinda Bachini, Director of Advocacy of CCF, provided an update about the foundation’s advocacy and patient support initiatives. The goal of the CCF’s advocacy group is to provide educational and emotional support for the cholangiocarcinoma (CCA) community of patients and caregivers, and to empower them with the knowledge and guidance needed to self-advocate.

The Cholangiocarcinoma Foundation (CCF) is encouraging healthcare professionals to support the adoption of the new International Classification of Diseases, 11th Revision (ICD-11), and its role in creating more robust epidemiological data for cholangio­carcinoma (CCA).